Intranasal BCG vaccination protects BALB/c mice against virulent Mycobacterium bovis and accelerates production of IFN‐γ in their lungs

• Published in: Clinical and experimental immunology Vol. 126; no. 2; pp. 274 - 279
• Main Authors: Lyadova, I. V., Vordermeier, H. M., Eruslanov, E. B., Khaidukov, S. V., Apt, A. S., Hewinson, R. G.
• Format: Journal Article
• Language: English
• Published: Oxford, UK Blackwell Science Ltd 01-11-2001; Blackwell; Oxford University Press; Blackwell Science Inc
• Subjects: Administration, Intranasal; Animals; BCG; BCG Vaccine - administration & dosage; Cytokines - biosynthesis; g-Interferon; Hypersensitivity, Delayed; immunity in the lung; Immunity to Infection; In Vitro Techniques; Interferon-gamma - biosynthesis; intranasal vaccination; Lung - immunology; Lymphocyte Activation; M. bovis infection; Male; Mice; Mice, Inbred BALB C; Mycobacterium bovis; Mycobacterium bovis - immunology; Mycobacterium bovis - pathogenicity; T-Lymphocytes - immunology; Tuberculosis - immunology; Tuberculosis - prevention & control; Virulence
• ISSN: 0009-9104; 1365-2249
• DOI: 10.1046/j.1365-2249.2001.01667.x

Local immune reactivity in the lungs of BALB/c mice was studied following (i) intranasal (i.n.) vaccination with Mycobacterium bovis BCG, (ii) intravenous (i.v.) challenge with a virulent M. bovis field isolate and (iii) i.n. vaccination with M. bovis BCG followed by i.v. challenge with an M. bovis field isolate. The results demonstrated that i.n. vaccination with BCG induced a high degree of protection against systemic M. bovis challenge, and that this protection correlated with a rapid production of IFN‐γ after M. bovis challenge by lung T cells from vaccinated mice.